Subsequently, gain-of-function mutations in the tyrosine kinase receptor KIT and platelet-derived growth factor receptor-α (PDGFRA) were groundbreakingly found as the main oncogenic driver in GIST [33, 34], which encouraged the development of GIST targeted therapies [5]. Here, NTRK1 is linked to gastrointestinal stromal tumor.